Abstract
Heart failure (HF) and diabetes mellitus (DM) commonly co-exist, with a prevalence of DM of up to 40 % in HF patients. Treatment of DM in patients with HF is challenging since many of the contemporary therapies used for the treatment of DM are either contraindicated in HF or are limited in their use due to the high prevalence of co-morbidities such as significant renal dysfunction. This article presents an overview of the physiology of the incretin system and how it can be targeted therapeutically, highlighting implications for the management of patients with DM and HF. Receptors for the incretin glucagon-like peptide-1 (GLP-1) are expressed throughout the cardiovascular system and the myocardium and are up-regulated in HF. GLP-1 therapy improves cardiac function in animal models of HF through augmented glucose uptake in the myocardium mediated through a p38 MAP kinase pathway. Small clinical studies have shown that GLP-1 improves ejection fraction, reduces BNP levels and enhances functional capacity in patients with chronic HF. A number of randomized controlled trials are currently underway to define the utility of targeting the incretin system in HF patients with DM. Incretin-based therapy may represent a novel therapeutic strategy in the treatment of HF patients with diabetes, in particular for their cardioprotective effects independent of those attributable to tight glycemic control.
Similar content being viewed by others
References
Sicree BR, Shaw J, Zimmet P (2010) The global burden diabetes and impaired glucose tolerance. Diabetes 27:1–105
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10):1134–1146
Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V-P et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27(22):2725–2736
Jr. KFA, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209–216
MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R et al (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29(10):1224–1240
Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94(3):311–321
Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29–34
Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S et al (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23(3):213–218
Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, De Groote P (2003) Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2(1):1
Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG et al (2010) Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Cardiac Fail 16(9):761–768
Deaton C, Mamas Ma, Rutter MK, Gibson M, Bowell S, Byrne R (2011) Glucose and insulin abnormalities in patients with heart failure. Eur J Cardiovasc Nurs 10(2):75–87
Fisman EZ, Tenenbaum A (2009) A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8:38
Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ Br Med J 335(7618):497
Yale J-F (2005) Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 16(Suppl 1):S7–S10
Shaw JS, Wilmot RL, Kilpatrick ES (2007) Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 24(10):1160–1163
Lago R, Singh P, Nesto R (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370(9593):1129–1136
Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ et al (2010) Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31(7):824–831
Robertson C Incretin-related therapies in Type 2 diabetes: a practical overview. Diabetes Spectr
Elrick H, Stimmler L, Hlad CJ, Arai Y (1964) Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24(10):1076–1082
Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Investig 46(12):1954–1962
Girard J (2008) The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes metab 34(6 Pt 1):550–559
Brown JC, Dryburgh JR (1971) A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 49(8):867–872
Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28(9):704–707
Drucker DJ, Nauck Ma (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696–1705
Lovshin Ja, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nature reviews. Endocrinol 5(5):262–269
Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48(9):1882–1890
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S–S, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18):2340–2350
Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6):2131–2157
Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen Y-T et al (2010) Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3(4):512–521
Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86(8):3717–3723
Meier JJ, Nauck Ma (2010) Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 59(5):1117–1125
Holst JJ Incretin Mimetics in the Treatment of Type 2 Diabetes Mellitus. Endocrine
Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H et al (2010) DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33(6):1255–1261
Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B et al (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes obes Metab 8(4):419–428
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Am Diabetes Assoc
Kendall DM, Cuddihy RM, Bergenstal RM (2009) Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 122(6):S37–S50
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Informa UK Ltd, UK
Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA et al (2004) The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44(8):1587–1592
Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60(4):470–512
NICE clinical guideline 87—The management of type 2 diabetes. 2009
Guideline Network SI. Management of diabetes: a national clinical guideline. SIGN; 2010
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al (2009) Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32(1):193–203
Van Gaal LF, Gutkin SW, Nauck Ma (2008) Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol/Eur Fed Endocr Soc 158(6):773–784
Ahluwalia R, Vora J (2011) Emerging role of insulin with incretin therapies for management of type 2 diabetes. J manag care pharm 2(3):146–161
Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378(9786):182–197
Beadle RM, Frenneaux M (2010) Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart Brit Cardiac Soc 96(11):824–830
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8):955–961
Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T et al (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317(3):1106–1113
Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP (2008) Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1(3):153–160
Vyas AK, Yang K-C, Woo D, Tzekov A, Kovacs A, Jay PY et al (2011) Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE 6(2):8
Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A et al (2010) VASCULAR Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 1–14
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L (2004) Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes vasc Dis Res 1(1):40–43
Sokos GG, Nikolaidis La, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Fail 12(9):694–699
Read PA, Hoole SP, White PA, Khan FZ, O’Sullivan M, West NEJ et al (2011) A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc interv 4(3):266–272
Read PA, Khan FZ, Dutka DP (2011) Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart (British Cardiac Society). May 10
Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R et al (2010) Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298(3):H1096–H1102
Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A et al (2012) Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 13:1–10
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885
Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 10(1):22
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34(1):90–95
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, M.A., Deaton, C., Rutter, M.K. et al. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 18, 141–148 (2013). https://doi.org/10.1007/s10741-012-9318-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-012-9318-y